SynCore Biotechnology Co.,Ltd, a biopharmaceutical company, engages in the research and development, manufacture, and marketing of drugs in the areas of oncology, ophthalmology, dermatology, and infectious diseases in Taiwan and internationally.
The last earnings update was 8 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
SynCore BiotechnologyLtd. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
SynCore BiotechnologyLtd's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as SynCore BiotechnologyLtd has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare SynCore BiotechnologyLtd's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare SynCore BiotechnologyLtd's earnings growth to the Taiwan, Province of China market average as no estimate data is available.
Unable to compare SynCore BiotechnologyLtd's revenue growth to the Taiwan, Province of China market average as no estimate data is available.
Unable to determine if SynCore BiotechnologyLtd is high growth as no earnings estimate data is available.
Unable to determine if SynCore BiotechnologyLtd is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
SynCore BiotechnologyLtd's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
SynCore BiotechnologyLtd's finances.
The net worth of a company is the difference between its assets and liabilities.
SynCore BiotechnologyLtd is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
SynCore BiotechnologyLtd's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
SynCore BiotechnologyLtd's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 22.1x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
Mr. Chih-Wen Lee is Chairman of Syncore Biotechnology Co., Ltd. and serves as its Director since June 09, 2008. Mr. Lee is Chief Executive Officer of SynCore Biotechnology Co.,Ltd. Mr. Lee founded Sinphar Pharmaceutical Co., Ltd. in 1977. He is an active member of the pharmaceutical industry and is well respected. Mr. Lee serves as Director of I-Lan Youngsun Education Foundation, Canadian Aging and Cancer Foundation, and Taiwan Cancer Foundation. Also, he serves as the council member of Society of Chinese Bioscientists in America, Pharmaceutical Division. His experience includes Chairman of Sinphar Pharmaceutical Co., Ltd.; Chairman of ZuniMed Biotech Co., Ltd.; Chairman of Sunetic Biotech Inc; Chairman of Universal Next Technology Inc and Director of Xing-Da Capital Crop. He served as president of Chinese-Canadian Academic and Professional Association, and the co-chairman of Pharmaceutical Market Conference organized by International Chinese Biotechnology Association. Mr. Lee also participates in Taiwanese National Development Assembly Forums and is a committeeman of Drug reviewing Committee of National Science Council. He holds BA, School of Pharmacy from Kaoshiung Medical University.
Chih-Wen's compensation has been consistent with company performance over the past year, both up more than 20%.
Chih-Wen's remuneration is higher than average for companies of similar size in Taiwan, Province of China.
Board of Directors Tenure
Average tenure of the
board of directors in years:
The tenure for the SynCore BiotechnologyLtd board of directors is about average.
Board of Directors
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
SynCore Biotechnology Co.,Ltd, a biopharmaceutical company, engages in the research and development, manufacture, and marketing of drugs in the areas of oncology, ophthalmology, dermatology, and infectious diseases in Taiwan and internationally. The company offers SB03-Veregen, an ointment for the treatment of patients with external genital and perianal warts; and distributes cameras under the epiCam name that is used in recording the progress of ophthalmology diseases. It is also involved in the development of SB01, an injectable anti-cancer NCE that is in Phase II clinical trial for the treatment of head and neck cancer; SB02, an anti-cancer NCE, which is in Phase I clinical trial for use in the treatment of stomach cancer; SB04 that is in Phase II/III clinical trial for the treatment of patients with dry age-related macular degeneration; and SB05, a composition of cytostatic drug paclitaxel combined with neutral and positive lipids, which is in Phase III clinical trials for the treatment of patients with triple negative breast cancer and pancreas cancer. The company was founded in 2008 and is headquartered in Yilan, Taiwan. SynCore Biotechnology Co.,Ltd is a subsidiary of Sinphar Pharmaceutical Co., Ltd.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.